You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. In Situ Autovaccination against Solid Cancers with Intratumoral Hiltonol Poly ICLC A phase II Adaptive Multicenter Clinical Study

    SBC: Oncovir            Topic: 102

    DESCRIPTION provided by applicant Hiltonol poly ICLC is a stabilized dsRNA therapeutic viral mimic or andapos danger signalandapos that activates multiple elements of innate and adaptive immunity It is a standalone immunomodulator but when properly combined with antigen it generates a comprehensive Th weighted immune response best suited for antiviral and antitumor action This project ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Preclinical development of a potent D-peptide RSV inhibitor

    SBC: NAVIGEN, INC.            Topic: NIAID

    PROJECT SUMMARYRespiratory syncytial virusRSVis the major cause of severe lower respiratory tract infections in children and infantsaffecting an estimatedmillion people and causing up todeaths worldwide per yearWHOIn the USyoung children andadults are hospitalized annually due to RSV infectionHigh risk adultsthe elderly and patients with chronic heart or lung diseaseexperience the highest RSV attr ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Improving vaccine development through high throughput immunogenicity screening

    SBC: Carterra, Inc.            Topic: NIAID

    Abstract Vaccines are fundamental in preventing debilitating illnesses and saving millions of lives each year But despite these vaccine oriented victories infectious diseases are still the second leading cause of death as well as the leading cause of disability adjusted life years worldwide About six million deaths were attributed to AIDS malaria and tuberculosis in regions where no vaccine ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Online professional development training for promotoras on lupus

    SBC: KDH Research & Communication, Inc.            Topic: NIMHD

    DESCRIPTION provided by applicant KDH Research and Communication KDHRC with the American College of Rheumatology ACR will develop LLPI Latinas con Lupus Promotoras con Informaci n Latinas with Lupus Promotoras with Information a culturally competent unique online professional development course course to improve the ability of promotoras de salud promotoras to raise awareness ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. I Live Inspired Individually Tailored and Integrated Social Support Network for Tobacco Cessation

    SBC: Live Inspired, LLC            Topic: NIDA

    DESCRIPTION provided by applicant Smoking kills Americans annually exacerbates myriad diseases and costs billions in healthcare and productivity losses Numerous barriers exist to accessing traditional treatment e g costs traveling to and scheduling appointments other logistics Text messaging is an extremely popular communication method Over of all Americans use text m ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Enhancing protective antibody responses for a DNA MVA HIV vaccine

    SBC: GEOVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The proposed work addresses a pivotal study for decisions on the form of the GeoVax Clade B HIV vaccine GOVX B to be taken into efficacy trials GOVX B is a DNA MVA vaccine that expresses virus like particles VLPs displaying trimeric membrane bound Env It has been under development for more than years during which time it has demonstrated unique pr ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Myocardial blood flow quantitation with the novel PET F Fluripidaz imaging tracer

    SBC: SYNTERMED INCORPORATED            Topic: NHLBI

    DESCRIPTION provided by applicant Myocardial blood flow quantitation with the novel F Flurpiridaz PET imaging tracer PROECT SUMMARY Coronary artery disease CAD is the single largest cause of death in the United States Prevention early diagnosis and treatment of CAD are essential to reduce the mortality Noninvasive assessments of regional myocardial blood flow at rest and during stress ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Therapeutic Approach to Hypercholesterolemia Using Anti PCSK Selected Immune Repertoires

    SBC: ABEOME CORPORATION            Topic: NHLBI

    DESCRIPTION provided by applicant We have developed and completed a proof of principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to PCSK injection and have identified a set of high affinity neutralizing antibodies which will be tested in animals for efficacy and potency PUBLIC HEALTH RELEVANCE Therapeutic and diagnostic app ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. HLS Hand held advanced functional imager for assessing local tissue oxygenation

    SBC: WASATCH PHOTONICS, INC.            Topic: NHLBI

    Summary We believe that our project is responsive to the HLS Small Business Topic of Special Interest for NHLBI Fiscal Year Here we will develop commercialization ready advanced functional imager to assess red blood cell RBC transfusion We successfully finished Phase I by developing the device s prototype and testing its functionality in the proof of principle experiments in scatter ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Novel DFG out inhibitors of Abl-kinases to treat PML

    SBC: Inhibikase Therapeutics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Inhibikase Therapeutics is a clinical stage biopharmaceutical company that has developed a host targeted mechanism of action to treat AIDS related and drug induced progressive multifocal leukoencephalopathy PML PML is a demyelinating disease of the central nervous system and was rarely seen clinically until the era of the HIV epidemic began in the mid s During the ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government